Cargando…

Deucravacitinib for the Treatment of Psoriatic Disease

Psoriasis is an immune-mediated disease, with the interleukin (IL)-23/IL-17 axis currently considered its main pathogenic pathway. Tyrosine kinase 2 (TYK2) is responsible for mediating immune signalling of IL-12, IL-23 and type I interferons, without interfering with other critical systemic function...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lé, Ana Maria, Puig, Luis, Torres, Tiago
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372960/ https://www.ncbi.nlm.nih.gov/pubmed/35960487 http://dx.doi.org/10.1007/s40257-022-00720-0

Ejemplares similares

Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far
por: Martins, Ana, et al.
Publicado: (2023)

Deucravacitinib: First Approval
por: Hoy, Sheridan M.
Publicado: (2022)

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
por: Mease, Philip J, et al.
Publicado: (2022)

Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis
por: Jin, Joy Q, et al.
Publicado: (2023)

Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects
por: Chimalakonda, Anjaneya, et al.
Publicado: (2022)

Successful treatment of refractory subacute cutaneous lupus erythematosus with deucravacitinib
por: Bouché, Nicole, et al.
Publicado: (2023)

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
por: Potestio, Luca, et al.
Publicado: (2023)

Upadacitinib for the treatment of psoriatic arthritis
por: Fonseca, Diogo, et al.
Publicado: (2023)

Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial
por: Thaçi, Diamant, et al.
Publicado: (2022)

Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report
por: Oliel, Sarah, et al.
Publicado: (2023)

Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects
por: Jing, Shan, et al.
Publicado: (2023)

An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far
por: Oliveira, Daniel G, et al.
Publicado: (2021)

Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis
por: Puig, Lluís
Publicado: (2017)

First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2
por: Catlett, Ian M., et al.
Publicado: (2022)

Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
por: Chimalakonda, Anjaneya, et al.
Publicado: (2021)

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
por: Armstrong, April W., et al.
Publicado: (2023)

Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
por: Iznardo, Helena, et al.
Publicado: (2021)

Dual inhibition of IL-17A and IL-17F in psoriatic disease
por: Iznardo, Helena, et al.
Publicado: (2021)

Fast and Sensitive Bioanalytical Method for the Determination of Deucravacitinib in Human Plasma Using HPLC-MS/MS: Application and Greenness Evaluation
por: Mahesh, Pottabattula, et al.
Publicado: (2023)

Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
por: Armstrong, April W., et al.
Publicado: (2023)

Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis
por: Armstrong, April W., et al.
Publicado: (2023)

Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis
por: Mease, Philip J., et al.
Publicado: (2014)

The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials
por: Qiu, Jingyue, et al.
Publicado: (2023)

Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey
por: Lebwohl, Mark, et al.
Publicado: (2021)

The metabolomics of psoriatic disease
por: Yan, Di, et al.
Publicado: (2017)

Correction to: Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey
por: Lebwohl, Mark, et al.
Publicado: (2022)

Treatment guidelines in psoriatic arthritis
por: Ogdie, Alexis, et al.
Publicado: (2020)

Choosing the right treatment for patients with psoriatic arthritis
por: Noviani, Maria, et al.
Publicado: (2020)

Cardiovascular Comorbidities in Psoriatic Disease
por: Szentpetery, Agnes, et al.
Publicado: (2019)

JAK Inhibitors in Psoriatic Disease
por: Megna, Matteo, et al.
Publicado: (2023)

Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis
por: Bergman, Martin, et al.
Publicado: (2017)

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial
por: Morand, Eric, et al.
Publicado: (2022)

Psoriatic Disease and Tuberculosis Nowadays
por: Balato, Nicola, et al.
Publicado: (2012)

An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis
por: Chimenti, Maria Sole, et al.
Publicado: (2020)

Infliximab (Remicade) in the treatment of psoriatic arthritis
por: Mease, Philip
Publicado: (2006)

Ustekinumab for the treatment of psoriatic arthritis: an update
por: Davari, Parastoo, et al.
Publicado: (2014)

Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015)

OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis—Focus on Rocatinlimab and Amlitelimab
por: Lé, Ana Maria, et al.
Publicado: (2022)

Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies
por: Sánchez-Rodríguez, Guillermo, et al.
Publicado: (2023)

A Systematic Review With Network Meta-Analysis of the Available Biologic Therapies for Psoriatic Disease Domains
por: Torres, Tiago, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kefn0ja6vte69ma5d7gda14t6g